Press Release

Printer Friendly VersionView printer-friendly version << Back

/C O R R E C T I O N -- Protagonist Therapeutics, Inc./

In the news release, Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference, issued 11-Sep-2017 by Protagonist Therapeutics, Inc. over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Tuesday, September 26 from 8:35-9:05 AM in Grand Ballroom 1" rather than "September 26 from 9:45 - 10:15 am ET" as originally issued inadvertently. The complete, corrected release follows:

Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

MILPITAS, Calif., Sept. 11, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the Company's President and Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26 from 8:35-9:05 AM in Grand Ballroom 1. The conference is being held at the InterContinental New York Barclay Hotel in New York, NY.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

A live and archived audio webcast of the presentation can be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at

About Protagonist Therapeutics
Protagonist Therapeutics is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Lead peptide candidates, PTG-100 and PTG-200, are based on this approach. PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company plans to initiate clinical trials of PTG-200 in 2017 as a potential treatment for Crohn's disease.  The company recently entered into a worldwide collaboration with Janssen Biotech to co-develop and commercialize PTG-200.  Protagonist is also developing an injectable hepcidin mimetic, PTG-300, for the treatment of rare diseases such as beta-thalassemia, currently in a Phase 1 clinical trial.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia. For further information, please visit


View original content with multimedia:

SOURCE Protagonist Therapeutics, Inc.

Joan Kureczka, Kureczka/Martin Associates, Tel: +1-415-821-2413, email:; or For Investors: The Trout Group, Marcy Nanus, +1-646-378-2927,